Hillsdale Investment Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Hillsdale Investment Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.11M	Buy	+209,900	New	+$3.07M	0.08%	277

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hillsdale Investment Management's AUPH Position: Q1 2026 in Review

Hillsdale Investment Management opened a new position in Aurinia Pharmaceuticals (AUPH) in Q1 2026: 209,900 shares worth $3.11M. The stake represents 0.08% of the portfolio and ranks #277 among its holdings.

259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

Hillsdale Investment Management held 209,900 shares of Aurinia Pharmaceuticals worth $3.11M as of Q1 2026.
Aurinia Pharmaceuticals was a new Hillsdale Investment Management position in Q1 2026.
Aurinia Pharmaceuticals made up 0.08% of Hillsdale Investment Management's portfolio in Q1 2026, its #277 holding.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.